Syndax Pharmaceuticals Stock Price

0.41 (2.17%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Syndax Pharmaceuticals Inc SNDX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.41 2.17% 19.31 12:50:16
Open Price Low Price High Price Close Price Prev Close
19.02 18.781 19.31 18.90
Bid Price Ask Price Spread News
19.22 19.30 0.08 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,317 158,641 $ 19.02 $ 3,017,338 548,367 13.02 - 27.85
Last Trade Time Type Quantity Stock Price Currency
12:50:09 100 $ 19.31 USD

Syndax Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 931.68M 48.25M 47.36M $ 1.52M $ - -1.88 -10.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -9.38k 0.40%

more financials information »

Syndax Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SNDX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week19.1919.887818.5519.10433,0920.120.63%
1 Month18.4919.887817.0818.40397,0080.824.43%
3 Months23.4625.6813.0217.50864,939-4.15-17.69%
6 Months25.5627.118913.0220.11773,784-6.25-24.45%
1 Year15.3027.8513.0219.39622,3124.0126.21%
3 Years8.3027.853.3915.31401,75711.01132.65%
5 Years13.0927.853.3914.30314,9586.2247.52%

Syndax Pharmaceuticals Description

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Your Recent History
Syndax Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.